Pacific Biosciences of California, Inc. Increase (Decrease) in Contract with Customer, Asset
Pacific Biosciences of California, Inc. (PACB) reported Increase (Decrease) in Contract with Customer, Asset of $10.42 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2024-02-28
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2022-12-31 was $159.00K.
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2022-09-30 was $1.46M.
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2022-06-30 was $4.06M.
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2022-03-31 was -$1.95M.
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for fiscal 2023 was $10.42M, a 179.06% increase from fiscal 2022.
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for fiscal 2022 was $3.73M.
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for fiscal 2021 was -$25.74M.
- Pacific Biosciences of California, Inc. increase (decrease) in contract with customer, asset for fiscal 2020 was -$729.00K.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2023-12-31 | $10.42M 10-K · filed 2024-02-28 | |||
| 2022-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.62M derived: sum of 2 quarters · filed 2024-02-28 | $5.68M derived: sum of 3 quarters · filed 2024-02-28 | $3.73M 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $5.52M derived: sum of 2 quarters · filed 2022-11-08 | $3.58M 10-Q · filed 2022-11-08 | -$4.23M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $4.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $2.12M 10-Q · filed 2022-08-08 | -$5.69M derived: sum of 3 quarters · filed 2024-02-28 | -$14.22M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$1.95M 10-Q · filed 2022-05-06 | -$9.76M derived: sum of 2 quarters · filed 2024-02-28 | -$18.28M derived: sum of 3 quarters · filed 2024-02-28 | -$22.68M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$16.33M derived: sum of 2 quarters · filed 2024-02-28 | -$20.73M derived: sum of 3 quarters · filed 2024-02-28 | -$25.74M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$8.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$12.93M derived: sum of 2 quarters · filed 2022-11-08 | -$17.93M 10-Q · filed 2022-11-08 | -$19.48M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$9.40M 10-Q · filed 2022-08-08 | -$10.95M derived: sum of 3 quarters · filed 2023-02-28 | -$11.23M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$5.00M 10-Q · filed 2022-05-06 | -$6.55M derived: sum of 2 quarters · filed 2023-02-28 | -$6.83M derived: sum of 3 quarters · filed 2023-02-28 | -$6.70M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.83M derived: sum of 2 quarters · filed 2023-02-28 | -$1.70M derived: sum of 3 quarters · filed 2023-02-28 | -$729.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$280.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$152.00K derived: sum of 2 quarters · filed 2021-11-05 | $818.00K 10-Q · filed 2021-11-05 | -$929.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $1.10M 10-Q · filed 2021-08-06 | -$649.00K derived: sum of 3 quarters · filed 2022-02-28 | -$302.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $970.00K 10-Q · filed 2021-05-06 | -$777.00K derived: sum of 2 quarters · filed 2022-02-28 | -$430.00K derived: sum of 3 quarters · filed 2022-02-28 | -$1.39M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$1.40M derived: sum of 2 quarters · filed 2022-02-28 | -$2.36M derived: sum of 3 quarters · filed 2022-02-28 | -$2.13M 10-K · filed 2022-02-28 |
| 2019-09-30 | $347.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | -$617.00K derived: sum of 2 quarters · filed 2020-11-03 | -$387.00K 10-Q · filed 2020-11-03 | -$1.06M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$964.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$734.00K 10-Q · filed 2020-08-06 | -$1.41M derived: sum of 3 quarters · filed 2021-02-26 | -$692.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $230.00K 10-Q · filed 2020-05-08 | -$441.00K derived: sum of 2 quarters · filed 2021-02-26 | $272.00K derived: sum of 3 quarters · filed 2021-02-26 | -$110.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$671.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $42.00K derived: sum of 2 quarters · filed 2021-02-26 | -$340.00K derived: sum of 3 quarters · filed 2021-02-26 | -$33.00K 10-K · filed 2021-02-26 |
| 2018-09-30 | $713.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $331.00K derived: sum of 2 quarters · filed 2019-11-07 | $638.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$382.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$75.00K 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $307.00K 10-Q · filed 2019-05-03 | |||
| 2017-12-31 | $1.03M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |